People taking GLP-1 weight loss drugs like Ozempic started moving less
A new study presented at the ENDO 2026 meeting reveals that patients using GLP-1 weight loss drugs like Ozempic and Wegovy tend to become less physically active. Researchers suggest this decline in movement may be linked to a loss of lean muscle mass, highlighting the need for exercise during treatment.
Why it matters
As the popularity of weight-loss drugs surges, understanding their impact on lifestyle and muscle health is critical for long-term patient wellness.
People with obesity who lost weight while taking popular medications such as Ozempic, Wegovy, Mounjaro, and Zepbound became significantly less physically active, according to research presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Illinois.
The report presents scientific findings from a medical conference without editorializing or taking a stance on the drugs.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in